Here are 1-2 brief analogies for 22nd Century (XXII):

• Altria or Philip Morris, but making cigarettes with almost no nicotine through plant biotech.
• Like a plant genetics company (e.g., Corteva Agriscience), but specializing in developing medical-grade cannabis and hemp.

• VLN King and VLN Menthol King cigarettes: These are very low nicotine content tobacco and cigarette products designed for tobacco harm reduction.
• SPECTRUM research cigarettes: These are standardized research cigarettes primarily used in independent clinical studies.
• Hemp/Cannabis Plant Development: Through collaboration, the company focuses on developing hemp/cannabis plants with exceptional cannabinoid profiles and superior agronomic traits for various industries.

22nd Century Group, Inc. (XXII) primarily sells to other companies (B2B).

Based on the company description, its major customers fall into the following categories:

1. Retail and Wholesale Tobacco Distributors: These customers purchase 22nd Century's very low nicotine content tobacco and cigarette products (VLN King and VLN Menthol King) for distribution to retail outlets such as convenience stores, supermarkets, and specialty tobacco shops, which then sell to individual consumers.
2. Research Institutions and Government Agencies: These entities acquire SPECTRUM research cigarettes for use in independent clinical studies focused on tobacco harm reduction and nicotine research. This category includes universities, medical research centers, and governmental health organizations.
3. Hemp/Cannabis Industry Partners: Companies operating in the medical, therapeutic, and agricultural sectors are customers for 22nd Century's proprietary hemp/cannabis plants and related intellectual property, developed through its collaboration with Keygene N.V. These partners seek plants with exceptional cannabinoid profiles and superior agronomic traits for their own product development and applications.

Larry Firestone Chief Executive Officer

Larry Firestone was appointed Chairman and Chief Executive Officer of 22nd Century Group in November 2023. He brings over 40 years of experience in enterprise, operations, and financial management across both public and private companies, having held roles as CEO, CFO, and COO in various industries. Prior to joining 22nd Century, he served as Chief Financial Officer of Oakland Manager, a privately-held cannabis purveyor, and as Chairman of FirePower Technology, a privately-held manufacturer. His public company experience includes serving as CEO of Eastside Distilling, Inc. (EAST) and Qualstar Corp. (QBAK), and CFO of Advanced Energy Industries (AEIS) and Applied Films Corp. (AFCO). Mr. Firestone founded Firepower Technology, Inc. in 2014. He is recognized for his track record of turnaround and positive transformation, even with fast-growing public companies.

Daniel Otto Chief Financial Officer

Daniel Otto was appointed Chief Financial Officer in April 2024. He previously served as the Corporate Controller at 22nd Century Group. From 2007 to 2009, Mr. Otto was the Chief Restructuring Officer and CFO at OTTO Industries Europe BV. He also established, structured, and developed Compagnie Financière OTTO, a single family office, for 11 years starting in 1999. Earlier in his career, from 1991 to 1998, Mr. Otto was a Managing Director of Corporate Finance/M&A at Financière Galliera and a co-Manager of Galliera Investissements, a private equity fund.

Robert Manfredonia Executive Vice President of Sales and Marketing

Robert Manfredonia joined 22nd Century Group as Executive Vice President of Sales and Marketing in August 2024. He possesses nearly three decades of experience in regulated consumer products, with a significant background in the adult beverage industry encompassing spirits, wine, and beer. His previous roles include Senior Vice President of Retail Corporate Accounts at Bonavita Beverage Group and Eastside Distilling. Mr. Manfredonia also held positions at Miller Brewing Company and Southern Glazer's Wine and Spirits. He is the founder of Diamond Brands, Inc., established in 2012, and served as President at Beeline Holdings, Inc. from 2018 to 2020.

Scott Marion Vice President of Manufacturing Operations

Scott Marion currently serves as the Vice President of Manufacturing Operations and Finance at 22nd Century Group, Inc. He has over a decade of experience in finance and operations. Prior to his current role, Mr. Marion held various positions at Reynolds American Inc., including Senior Director of Operations Finance, Senior Director of Manufacturing Finance, and Director of Operations Finance, where he was responsible for financial support, cost of goods sold (COGS) management, and financial leadership for manufacturing sites. He has a proven track record in driving productivity savings, efficiency gains, and implementing capital projects.

Jonathan Staffeldt General Counsel

Jonathan Staffeldt was appointed General Counsel of 22nd Century Group in April 2024. Before this, he served as Deputy General Counsel for the company starting in January 2023. Previously, Mr. Staffeldt held the position of Chief Legal Officer at GVB Biopharma from September 2019. His background also includes private practice, where he gained substantial experience in corporate law, mergers and acquisitions, and litigation.

Here are the key risks to 22nd Century (symbol: XXII):

1. Regulatory Dependence and Market Adoption for Very Low Nicotine Content (VLNC) Products: 22nd Century's business strategy is heavily reliant on the U.S. Food and Drug Administration (FDA) establishing and enforcing a nationwide low nicotine content standard for all combustible tobacco products. Should this mandate be delayed, face legal challenges, or not be broadly adopted, the company's competitive advantage and market opportunity for its VLN products could be significantly limited. Furthermore, while VLNC cigarettes are intended for harm reduction, the company faces the risk of insufficient consumer adoption and potential misperceptions about the products' health benefits, particularly if higher-nicotine alternatives remain widely available. The company is currently in an early commercialization stage for its VLN products, and failure to meet sales targets and expand distribution could lead to continued gross profit losses due to fixed manufacturing costs.

2. Financial Viability and Unprofitability: 22nd Century is currently operating at a loss and is not projected to achieve profitability within the next three years. The company has experienced unstable profits over time, leading to significant stock drawdowns, and its share price has demonstrated high volatility. While the company maintains some net cash, its ongoing unprofitability and cash burn inherent to a company in its development stage could necessitate future capital raises, potentially leading to dilution for existing shareholders.

3. Regulatory and Market Challenges in the Hemp/Cannabis Sector: The company's collaboration in developing hemp/cannabis plants for various uses exposes it to the inherent risks of this evolving industry. The cannabis and hemp markets face significant regulatory uncertainties due to inconsistent legal frameworks, particularly in the United States where cannabis remains federally illegal, leading to potential policy shifts. This environment creates operational complexities, including high costs related to cultivation, compliance, and marketing. The market is also highly volatile, competitive, and susceptible to challenges from the illegal market, which can undermine the success of licensed businesses.

• Competition from established tobacco companies' Reduced-Risk Products (RRPs): Major tobacco companies are investing heavily in and marketing various alternative RRPs, such as e-cigarettes and heated tobacco products. If these alternative RRPs gain wider consumer acceptance and market share, or if these large companies leverage their extensive resources and distribution networks to effectively develop and market their own very low nicotine content (VLN) solutions, 22nd Century's VLN products could be marginalized or face overwhelming competition.
• Advanced Competition in Cannabis/Hemp Genetics: The rapidly evolving cannabis and hemp industry is characterized by significant investment in genetic research, breeding, and cultivation technologies from numerous players. If well-funded competitors, including specialized cannabis biotech firms, agricultural giants entering the space, or large pharmaceutical companies pursuing cannabinoid-based drugs, develop and patent strains with superior cannabinoid profiles, higher yields, or better disease resistance that outpace 22nd Century's collaboration efforts, 22nd Century's position in this segment could be severely challenged.

The addressable markets for 22nd Century Group's main products and services are substantial and growing:

• Very Low Nicotine Content (VLNC) Tobacco Products:

  The global tobacco harm-reduction products market, which includes alternatives designed to reduce health risks compared to combustible cigarettes, was valued at approximately USD 46.8 billion in 2025. This market is projected to reach USD 128.4 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.6%.

• Hemp/Cannabis for Medical, Therapeutic, and Agricultural Uses:

  • Medical Cannabis:

    The global medical cannabis market was valued at approximately USD 14.34 billion in 2024 and is anticipated to reach approximately USD 52.23 billion by 2034, with a CAGR of 13.8%. In the U.S., the medical marijuana market size surpassed USD 9.63 billion in 2023 and is projected to reach around USD 70.30 billion by 2033, growing at a CAGR of 21.99%.

  • Industrial Hemp:

    The global industrial hemp market size was valued at approximately USD 11.42 billion in 2025 and is projected to grow to approximately USD 71.53 billion by 2034, at a CAGR of 22.77%. The U.S. industrial hemp market is predicted to be valued at approximately USD 2.14 billion in 2025 and is expected to grow to approximately USD 12.71 billion by 2034, registering a CAGR of 21.9%.

  • Cannabis Pharmaceuticals (subset of therapeutic applications):

    The U.S. cannabis pharmaceuticals market generated revenue of USD 585.0 million in 2023 and is expected to reach USD 19,727.4 million by 2030, demonstrating a CAGR of 65.3% from 2024 to 2030.

22nd Century Group (symbol: XXII) anticipates several key drivers for future revenue growth over the next 2-3 years:

1. Expansion and Relaunch of VLN® Reduced Nicotine Content (RNC) Cigarettes: The company's proprietary VLN® products, which have received FDA Modified Risk Tobacco Product (MRTP) authorization, are a core focus for growth. 22nd Century is actively expanding the distribution of its branded VLN® products and aims for significant market penetration by increasing retail points and consumer awareness.
2. Growth in Higher-Margin Contract Manufacturing Operations (CMO): 22nd Century is strategically shifting its product mix to prioritize higher-margin conventional cigarette products within its contract manufacturing business. This includes securing new, profitable CMO contracts and reallocating production resources to improve overall margins and revenue quality.
3. Introduction of New Partner-Branded VLN® Products: As part of its VLN® expansion strategy, the company is collaborating with partners to launch co-branded VLN® products, such as the initial partnership with Smoker Friendly. This approach aims to accelerate market adoption and broaden the reach of its reduced nicotine content offerings.
4. Leveraging FDA MRTP Authorization: The FDA's Modified Risk Tobacco Product (MRTP) authorization for VLN® cigarettes provides a unique competitive advantage. This authorization allows 22nd Century to communicate the reduced nicotine content of its products, differentiating them in the market and potentially driving increased consumer adoption.

Capital Allocation Decisions (2021-2025)

Share Issuance

• In April 2025, 22nd Century Group announced a warrant inducement offering with an expectation to generate gross proceeds of approximately $5.4 million, potentially reaching up to $8.8 million if all warrants are exercised.
• In January 2025, the company issued 518,600 shares of common stock following conversion notices from debenture holders, totaling $3,132.
• A 1-for-15 reverse stock split was implemented in January 2026.

Inbound Investments

• In Q3 2025, 22nd Century Group received a $9.5 million insurance settlement.
• The company reported gaining new capital in September 2025 following debt repayment.
• As part of a comprehensive restructuring, the company achieved debt-free status in Q3 2025, strengthening its balance sheet and financial stability.

Outbound Investments

• In 2022, 22nd Century acquired GVB Biopharma.
• The GVB subsidiary was divested in December 2023, and all hemp-related research and development activities were terminated.

Capital Expenditures

• Capital expenditures in recent periods were -$0.05 million for the third quarter of 2025, -$0.14 million for fiscal year 2024, -$4.66 million for fiscal year 2023, and -$3.66 million for fiscal year 2022.
• The company prioritizes continuous investment in research and development (R&D) to develop next-generation nicotine delivery systems aimed at tobacco harm reduction.